

C Patrick Reynolds, MD PhD

Dr. Reynolds received his BA in Biology from The University of Texas at Austin, his MD from UT Southwestern Medical School in Dallas, TX, his PhD (Cell Biology) from UT Austin, and his pediatrics training at the National Naval Medical Center. His postdoctoral fellowship was in cancer immunology at UT Southwestern Medical School, Dallas, TX. His research focuses on retinoids as tumor-selective differentiation or cytotoxic agents, mechanisms of drug resistance and drugs to modulate resistance in childhood and adult cancers, development of novel preclinical testing models for childhood cancer drug development, and clinical trials testing novel therapeutic approaches for cancer. He is the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center, and is Director of the South Plains Oncology Consortium (SPOC; www.SPONC.org).

Dr. Reynolds is Chair of the Neuroblastoma Developmental Therapeutics Sub-committee and member of the steering committees for neuroblastoma and translational research for the Children's Oncology Group. He is a special government employee with the FDA and a member of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee for the FDA. He is a member of the New Approaches to Neuroblastoma Therapy (NANT) consortium Scientific Review Committee, a member of the Pediatric Oncology Task Force of the American Association for Cancer Research. He is a member of the Drug Discovery and Molecular Pharmacology Study Section for the National Cancer Institute and a member of the Best Pharmaceuticals for Children Act prioritization panel for the National Institute for Child Health and Development.

He sponsors multiple FDA Investigational New Drug (IND) applications and has active Rapid Access to Intervention Discovery (RAID), RO1, and PO1 grant support from the National Cancer Institute (NCI) and also a cancer research grant from the Department of Defense. He is the Principal Investigator of the NCI-funded Pediatric Preclinical Testing Program (PPTP) cell culture laboratory. His laboratory serves as the Cell Culture Repository and the Ewing's Family Tumors Preclinical Testing Lab for the Children's Oncology Group. Dr. Reynolds is an author or co-author of more than 180 scientific papers and is an Associate Editor for *Clinical Cancer Research*.